Davide Brambilla

Prof. Dr. Davide Brambilla

University of Montreal, Montreal, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
NPNevena Paunović
Nevena Paunović
YBYinyin Bao
Yinyin Bao
FCFergal Brian Coulter
Fergal Brian Coulter
KMKunal Masania
Kunal Masania
AGAnna Karoline Geks
Anna Karoline Geks
JLJean-Christophe Leroux
Jean-Christophe Leroux
Customized bioresorbable airway stents with elasticity similar to silicone were 3D printed by digital light processing.

2 May 2025 in Journal of Controlled Release
Verified
Journal Article
Open access
FMFatma Moawad
Fatma Moawad
RPRoxane Pouliot
Roxane Pouliot
DBDavide Brambilla
Davide Brambilla
Microneedles (MNs) have emerged as an innovative approach for transdermal drug delivery, offering an efficient and minimally invasive alternative to conventional injections and oral delivery systems. While their potential has been widely recognized and extensively studied, the translation of MN technology into clinical practice remains limited. Despite the vast amount of published research, much of it involves over-complexification without addressing the core barriers to practical application. For example, dissolving/degradable MNs face key limitations such as poor drug loading capacity, low dosing consistency, and challenges in delivering effective therapeutic concentrations. These constraints restrict their utility to niche applications, such as vaccination or delivering potent drugs that require minimal doses. Additionally, the lack of standardized quality control measures, the complex manufacturing processes, and the high costs associated specifically with sterile/aseptic production further impede clinical translation. Regulatory frameworks for MNs remain vague, slowing the development of products that meet approval standards. This review critically examines the fundamental barriers to dissolving/degradable MN commercialization, as the most studied type of MN, while exploring promising strategies to overcome them. Advances in formulation science, fabrication techniques, and material engineering have demonstrated potential in enhancing drug loading efficiency and delivery consistency. Moreover, the establishment of clearer regulatory guidelines and scalable production strategies could significantly accelerate the commercialization of MN technology. By shifting focus toward pragmatic and clinically relevant solutions, this review aims to bridge the gap between research innovations and real-world applications, paving the way for broader implementation of MN technology in medicine.

16 August 2021 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
ELElise Laszlo
Elise Laszlo
GCGregory De Crescenzo
Gregory De Crescenzo
ANAlfonso Nieto‐Argüello
Alfonso Nieto‐Argüello
XBXavier Banquy
Xavier Banquy
DBDavide Brambilla
Davide Brambilla

3 December 2018 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
Kun LiangKun Liang
Kun Liang
DBDavide Brambilla
Davide Brambilla
JLJean‐Christophe Leroux
Jean‐Christophe Leroux

23 October 2018 in Small
Verified
Journal Article
Closed access
PDF file
SBSamuel Babity
Samuel Babity
MRMahdi Roohnikan
Mahdi Roohnikan
DBDavide Brambilla
Davide Brambilla

17 December 2021 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
SBSamuel Babity
Samuel Babity
FCFrédéric Couture
Frédéric Couture
ECEstefânia V. R. Campos
Estefânia V. R. Campos
SHSarah Hedtrich
Sarah Hedtrich
RHRaphael Hagen
Raphael Hagen
DBDavide Brambilla
Davide Brambilla